Skip to main content

Table 2 Demographic data, the patient characteristics and ECMO data of 8 multicentre studies with H1N1 outbreak (2009–2010)

From: ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review

Study group

Data collection/population

ECMO pts./total H1N1 pts.

Age of ECMO pts. (years)

PaO2/FIO2a (mmHg)

MV durationa (days)

ECMO duration (days)

Discharged aliveb, n (%)

ANZ ECMO Influenza Investigator [40]

Retrospective/15 ICUs

68/194

34.4 (26.6–43.1)

56 (48–63)

NA

10 (7–15)

32 (47.1%)

UK ERP with SwiFT study [41]

Prospective/4 centres

75c

36.5 ± 11.4

54.9 ± 14.3

4.4 ± 3.7

NA

57 (76%)

Italian ECMO network [42]

Prospective/14 ICUs

60/153

39 (32–46)

63.3 (56–79)

2 (1–5)

10 (7–17)

41 (68.3%)

Australian ERP [43]

Retrospective

38

NA

63

NA

NA

33 (86.8%)

Japanese Society [44]

Retrospective/12 ICUs

14

54

50 (40–55)

5 (0.8–8.5)

8.5 (4.0–10.8)

5 (35.73%)

REVA Research Network in France [45]

Prospective/114 ICUs

123

42 ± 13

63 ± 21

2 (1–5)

9.8

79 (64.2%)

Germany ARDS network [46]

Retrospective/40 centres

61/116

42 (39–45)d

87 (74–101)d

NA

NA

28 (45.9%)

Italian ECMO network [47]

Prospective/14 centres

60

39.7 ± 12

NA

NA

NA

41 (68.3%)

  1. Mean ± SD or median (interquartile range)
  2. ANZ Australia and New-Zealand, ECMO extracorporeal membrane oxygenation, ERP ECMO Retrieval Program, ICU intensive care unit, MV mechanical ventilation, NA not applicable, pts. patients, SwiFT Swine Flu Triage
  3. aData before ECMO support
  4. bDischarged alive of patients who underwent ECMO support
  5. cMatched pairs among total 80 ECMO referred patients
  6. dMean values (95% confidence interval)